Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. | Bicycle Therapeutics is ...

When you think of biotech hubs, the first image that comes to mind may be the sleek waterfront offices of Boston Seaport or ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

Longevity company Altos Labs has secured a new clinical leader from the eye of the storm. Former Tornado Therapeutics ...

Genomics is stepping up to buy Scale Biosciences and its single-cell profiling solutions, with plans to implement them within ...

A group of more than a dozen investors have together purchased a majority stake in HistoSonics, following reports earlier ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

After emerging from stealth earlier this year, Apreo Health has raised $130 million to breathe new life into the development ...

After launching an expanded incubator for early-stage biotechs late last year, Charles River Laboratories is now looking to give participants access to crowdsourced cash. | After launching an ...

In its own statement, Edwards said it disagrees with the FTC’s belief that the acquisition will limit access to a new therapy ...

Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential ...